Goserelin Other names: Goserelin acetate

Chemical formula: C₅₉H₈₄N₁₈O₁₄ Molecular mass: 1,269.411 g/mol PubChem compound: 5311128

Therapeutic indications

Goserelin is indicated for:

Prostate cancer

Population group: men, only adults (18 years old or older)

Treatment of prostate cancer in the following settings:

In the treatment of metastatic prostate cancer where goserelin has demonstrated comparable survival benefits to surgical castrations.
In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where goserelin has demonstrated comparable survival benefits to an anti-androgen.
As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where goserelin has demonstrated improved disease-free survival and overall survival.
As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where goserelin has demonstrated improved disease-free survival.
As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where goserelin has demonstrated improved disease-free survival.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.6 mg once every 28 days

Oestrogen receptor (ER) positive breast cancer

Population group: women, only adults (18 years old or older)

Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation.
Goserelin is indicated as an alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogen receptor (ER) positive early breast cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.6 mg once every 28 days

Uterine fibroids

Population group: women, only adults (18 years old or older)

In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.6 mg once every 28 days

Endometriosis

Population group: women, only adults (18 - 65 years old)

In the management of endometriosis, goserelin alleviates symptoms, including pain, and reduces the size and number of endometrial lesions.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.6 mg once every 28 days

Assisted reproduction

Population group: women, only adults (18 - 65 years old)

Pituitary downregulation in preparation for superovulation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.6 mg once

Endometrial thinning

Population group: women, only adults (18 - 65 years old)

Goserelin is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.6 mg once every 28 days

Contraindications

Goserelin is contraindicated in the following cases:

Pregnancy

at least one of

Lactation
Pregnancy

Lactation

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈